- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- AZD5363 PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
| Phase 1 | Phase 2 | Phase 3 |
|---|
TAS1440
Oral LSD1 inhibitor (Hematological Malignancies)
| . |
Ownership: Taiho
Mechanism of Action: Lysine-Specific Histone Demethylase 1 (LSD1) inhibition
Indication: Relapsed/refractory Acute Myeloid Leukemia (AML)
How this therapy can help
TAS1440 is a Lysine-Specific Histone Demethylase 1 inhibitor (LSD1 [also named KDM1A]). LSD1 is an epigenetic regulator. It is aberrantly expressed in many cancers, including AML, where it impedes cellular differentiation which may contribute to leukemia development, cancer cell proliferation, cell metastasis, and invasiveness, and is associated with inferior prognosis.
Clinical status
TAS1440 is being evaluated in a first-in-human Phase 1 clinical study in patients with relapsed/refractory AML.